Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Telaprevir intermediate in B crystal form and synthesis method thereof

A technology of telaprevir and a synthesis method, applied in the field of drug synthesis, can solve problems such as low purity, influence on drug efficacy, etc., and achieve the effects of good appearance, good temperature and humidity stability, and short use time

Inactive Publication Date: 2014-01-01
SUZHOU UUGENE BIOPHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Although the above-mentioned three synthetic methods finally synthesized the telaprevir intermediate (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl) glycyl-3-methyl-L-valine , but the synthesized telaprevir intermediates are all white solids (white solid), the purity is not high, and the crystal form and other physical properties of the intermediates are not described in the above three documents, and these are all May affect the potency of the final product

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Telaprevir intermediate in B crystal form and synthesis method thereof
  • Telaprevir intermediate in B crystal form and synthesis method thereof
  • Telaprevir intermediate in B crystal form and synthesis method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] 10g telaprevir intermediate (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl) glycyl-3-methyl-L-valine was added to 25mL absolute ethanol, in Heat to reflux at 80°C until the solution is clear, concentrate to dryness at 40°C, then add 50mL of ethyl acetate to make slurry for 4 hours, let stand, collect crystals by suction filtration, and dry to obtain 9.3g telaprevir intermediate Form B (the crystal lattice contains a small amount of ethyl acetate solvent). The purity is 99.10%, and the chiral purity is 100%.

Embodiment 2

[0053] Under stirring, add 30mL absolute ethanol to 10g telaprevir intermediate (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valine , heated at 80°C until the telaprevir intermediate was completely dissolved to form a reaction liquid, and when the reaction liquid was cooled to 30°C, n-heptane was added until all the solids were precipitated, stirred for 4 hours and left to stand, the crystals were collected by suction filtration, and dried , to obtain 8.7 g telaprevir intermediate B crystal form. The purity is 99.36%, and the chiral purity is 99.86%.

Embodiment 3

[0055] Under stirring, 40mL dichloromethane was added to 5g telaprevir intermediate (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valine , heated and refluxed at 40° C. for 3 hours, cooled naturally to room temperature, collected crystals by suction filtration, and dried to obtain 4.2 g of telaprevir intermediate B crystal form. The purity is 99.30%, and the chiral purity is 99.62%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Wavelengthaaaaaaaaaa
Injection volumeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a telaprevir intermediate (2S)-2-cyclohexyl-N-(2-pyrazinyl carbonyl)-glycyl-3-methyl-L-valine in a B crystal form, and a synthesis method thereof, and belongs to the technical field of drug synthesis. The telaprevir intermediate in the B crystal form is subjected to Cu-Ka radiation by adopting X-ray powder diffraction at the angle of 2 times of Theta, characteristic peaks appear at the points of 5.5+ / -0.2, 7.4+ / -0.2, 10.7+ / -0.2, 16.7+ / -0.2, 17.4+ / -0.2, 17.6+ / -0.2, 18.4+ / -0.2, 19.2+ / -0.2, 20.5+ / -0.2, 21.5+ / -0.2, and 22.1+ / -0.2; the solid is white, the melting point is 221.6-229.3 DEG C, the moisture content is 0.1-0.5 percent, and the residue solvent is 8-12 percent. The invention further discloses the synthesis method for the telaprevir intermediate in the B crystal form. The telaprevir intermediate in the B crystal form is good in appearance, small in moisture content, high in temperature and humidity stability, and high in purity.

Description

technical field [0001] The present invention relates to a telaprevir intermediate and a synthesis method thereof, in particular to a telaprevir intermediate (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3 -Methyl-L-valine B crystal form and a synthesis method thereof, belonging to the technical field of pharmaceutical synthesis. Background technique [0002] Telaprevir (TVR), chemical name: (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(carbonylpyrazine)-glycyl-3-methyl-L-valyl -N-(1S)-1-[(cyclopropylamino)-oxoacetyl]butyl-octahydrocyclopenta[c]pyrrole-1-carboxamide, CAS registration number: 402957-28-2, is a A drug that inhibits HCV genotype 1 NS3 / 4A serine protease and can terminate HCV replication. Acts as a protease inhibitor by binding to the virus and preventing its proliferation. The structural formula of telaprevir is as follows: [0003] [0004] In May 2011, the U.S. FDA approved the listing of telaprevir from Vertex Pharmaceuticals, whose trade name is Incivek, for ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K5/097C07K1/30
Inventor 胡凡王伸勇李胜王晓俊胡隽恺
Owner SUZHOU UUGENE BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products